Background and Aim: Pathological cardiac hypertrophy is observed in pressure overload of the left ventricle. Elevated intracellular cGMP-levels have been reported to prevent the development of pathological myocardial hypertrophy. We investigated the effects of the chronic activation of the cGMP producing enzyme, soluble guanylate cyclase (sGC) by cinaciguat in a rat model of pressure overload-induced cardiac hypertrophy. Methods: We performed aortic banding (AB) to evoke pressure overload-induced cardiac hypertrophy in our rats. Sham operated on animals served as controls. Experimental and control groups were treated with 10 mg/kg/day cinaciguat (Cin) or placebo (Co) p.o., respectively. The development of cardiac hypertrophy was investigated by echocardiography. We performed the left ventricular (LV) pressurevolume analysis with a pressure-conductance microcatheter to assess the cardiac function. In addition to our functional experiments, histological and molecular biological measurements were carried out. Conclusion: Our results demonstrate that chronic stimulation of the NO-cGMP signaling pathway by pharmacological activation of the soluble guanylate cyclase might be a novel therapeutic approach in the prevention of pathological myocardial hypertrophy.
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